All In Biotech

Drug Trial Radar · NCT07223229

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Dec 30, 2025

Primary completion

Dec 31, 2026

Study completion Sep 30, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.

Conditions

  • Non-segmental Vitiligo

Interventions

  • EI-001Biological

    EI-001 drug product is supplied as a colorless to slightly yellow and sterile solution for infusion with a protein concentration of 10.0 mg/mL

  • PlaceboOther

    0.9% sterile sodium chloride solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in F-VASI from baselineTime frame: Week 24

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Marvel Clinical Research

    Huntington Beach, California · Recruiting

  • Skin Care Research, LLC

    Hollywood, Florida · Recruiting

  • U Mass Chan Medical School

    Worcester, Massachusetts · Withdrawn

  • Apex Clinical Research Center (Lorain)

    Lorain, Ohio · Recruiting

  • Apex Clinical Research Center, LLC (Mayfield)

    Mayfield Heights, Ohio · Recruiting

  • Center for Clinical Studies

    Houston, Texas · Recruiting

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, Taiwan · Recruiting

  • Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Niao-Sung, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.